A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With R-CHOP With or Without Radiotherapy
A Prospective Observational Study of Newly Diagnosed Diffuse Large B Cell Primary Breast Lymphomas Treated With R-CHOP With or Without Radiotherapy
In this study, the investigators propose that the addition of rituximab will lower the risk of systemic and local relapses in patients with localized PBL. Patients will be treated with 6 cycles of RCHOP-14 or RCHOP-21. The administration of radiotherapy following chemotherapy is strongly recommended, based on the findings of the retrospective IELSG study, but will be at the discretion of the treating center.
Inclusion Criteria:
Previously untreated patients with DLBCL of the breast.
Patients must have CD20 positive tumors.
Stage IE or IIE.
Must have at least one objective measurable or evaluable disease. Baseline measurements and evaluations must be obtained within 4 weeks of registration to the study.
Patients must have an ECOG performance status 0-2.
Patients must have adequate organ function as evidenced by the following laboratory studies ( within 2 weeks prior to registration):
Patients must be age > 18 years.
Patients must have a normal left ventricular ejection fraction to be eligible.
Exclusion Criteria: